Preferred Label : Hyperphenylalaninemia, bh4-deficient, a;
Symbol : HPABH4A;
CISMeF acronym : HPABH4A;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Hyperphenylalaninemia, tetrahydrobiopterin-deficient, due to pts deficiency; 6-pyruvoyl-tetrahydropterin synthase deficiency; Pts deficiency; PTSD; PTPSD;
Included titles and symbols : Hyperphenylalaninemia, bh4-deficient, due to partial pts deficiency;
Description : Tetrahydrobiopterin (BH4)-deficient hyperphenylalaninemia (HPA) comprises a genetically
heterogeneous group of progressive neurologic disorders caused by autosomal recessive
mutations in the genes encoding enzymes involved in the synthesis or regeneration
of BH4. BH4 is a cofactor for phenylalanine hydroxylase (PAH; 612349), tyrosine hydroxylase
(TH; 191290) and tryptophan hydroxylase (TPH1; 191060), the latter 2 of which are
involved in neurotransmitter synthesis. The BH4-deficient HPAs are characterized phenotypically
by hyperphenylalaninemia, depletion of the neurotransmitters dopamine and serotonin,
and progressive cognitive and motor deficits (Dudesek et al., 2001).;
Inheritance : Autosomal recessive;
Molecular basis : Caused by mutation in the 6-@pyruvoyl-tetrahydropterin synthase gene PTS, (612719.0001);
Laboratory abnormalities : Hyperphenylalaninemia; Decreased homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) in CSF; Increased neopterin in urine and CSF; Decreased or absent PTS activity;
Prefixed ID : #261640;
Origin ID : 261640;
UMLS CUI : C0878676;
- Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- DO Cross reference
- Genes related to phenotype
- HPO term(s)
- ORDO concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to NTBT